Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose from 378 million people with the disease in 1990 to 788 million in 2023 as the world population grew and aged, making it for the first time a top 10 cause of death worldwide. 

About The Study: The findings of this study support the routine use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve kidney outcomes across the full spectrum of kidney function and albuminuria among patients with type 2 diabetes, chronic kidney disease, or heart failure. 

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce the risk of kidney disease progression, hospitalisation, and death in people with and without diabetes, regardless of their kidney function.

A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and death, a new study shows.

The American College of Cardiology (ACC) and OpenEvidence are entering a strategic partnership to accelerate the translation of cardiovascular clinical guidance and research into clinical implementation at the point of care. By combining ACC’s leadership in cardiovascular science and education with OpenEvidence’s advanced generative artificial intelligence (AI) technology, clinicians will have access to the latest relevant and actionable medical evidence to support shared decision-making with their patients.

Fewer than half of young adults with severely high low-density lipoprotein (LDL-C), or “bad” cholesterol, levels start taking a statin within five years of first high LDL-C measurement, according to a study published in JACC, the flagship journal of the American College of Cardiology, and presented at the American Heart Association’s 2025 Scientific Sessions. The 2018 ACC/AHA Cholesterol Guideline recommends a statin in patients with LDL-C over 190 mg/dL and these findings highlight significant care gaps in lipid management among adults aged 18 to 39, particularly those at high risk for premature atherosclerotic cardiovascular disease (ASCVD).

A new study found that gut microbes likely play a role in coronary artery disease (CAD).

People with signs of damage to their heart during middle age are more likely to develop dementia in later life, according to a new study led by UCL (University College London) researchers.